Navigation Links
Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
Date:7/22/2010

CARY, N.C., July 22 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it will host a conference call at 8:30 AM ET on Thursday, August 5, 2010, to discuss its financial results for the quarter and six months ended June 30, 2010.  Management will also provide an update on the Company's strategy, operations and product development pipeline.  Cornerstone intends to issue its financial results press release prior to the conference call.

To participate in the live conference call, please dial 800-561-2813 (U.S. callers) or 617-614-3529 (international callers), and provide passcode 12677542.  A live webcast of the call will also be available through the Investor Relations section of the Company's website.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on August 5, 2010, by dialing 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), and providing passcode 28082122.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians, key retail pharmacies and hospitals with its specialty sales forces. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales forces; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 4, 2010 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Therapeutics Announces Management Change
2. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
3. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
4. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
5. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
6. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
7. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
8. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
9. Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
10. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
11. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  While nearly three-quarters of ... can have on their health, only about half report ... to the results of a new survey announced today ... the start of National Osteoporosis Month, Hologic is raising ... affects nearly 56 million Americans. Osteoporosis is ...
(Date:5/2/2016)... SAN FRANCISCO , May 2, 2016 /PRNewswire/ ...  is expected to reach USD 11.1 billion by ... Grand View Research, Inc. Major drivers of the ... in therapeutic areas and government recommendations for periodic ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... 02, 2016 , ... The National Resident Matching Program® (NRMP®) ... (“the Match”), the system through which U.S. and international medical school students and ... were placed in the 2016 Match, and 29,572 were filled when the matching ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Dr. Philip ... his patients with same day treatments. In the past, many necessary dental treatments could ... work, along with multiple anesthetic shots and extra chair time. Not only could this ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , ... can visit Dr. Assili to receive any dental extraction treatment for $40 off the ... June 30, 2016. With the lower price, patients can more easily afford extractions to ...
(Date:5/2/2016)... ... , ... This week Omega Institute, a premier nonprofit educational retreat center in ... Omega is offering a record 370 in-person workshops and new online learning opportunities ... interest in or need for the knowledge and skills we’ve been cultivating for nearly ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies for their ... from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results ...
Breaking Medicine News(10 mins):